Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma.
glioblastoma
magnetic resonance imaging
survival
treatment
tumor treating field (TTF) therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
08
2022
accepted:
28
12
2022
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150-300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients' scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9-77.8 years (mean age 47.3±11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0-76.7 years (mean age 51.4±12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected. Patients on TTFields therapy demonstrated improvements in PFS and OS relative to controls (hazard ratio: 0.64, p=0.031; and 0.61, p=0.028 respectively). TTFields average time on therapy was 74.8% (median 82%): median PFS of these patients was 19.75 months. Seven patients with TTFields usage ≤60% (23-60%, mean 46.3%, median 53%) had a median PFS of 7.95 months (p=0.0356). Control patients with no TTFields exposure had a median PFS of 12.45 months. Median OS of TTF patients was 31.67 months compared to 24.80 months for controls. This is the most extensive study on newly-diagnosed GBM patients treated with TTFields, covering a period of 18 years at a single center and presenting not only data from clinical trials but also a group of 36 patients treated with TTFields as a part of routine clinical practice.
Identifiants
pubmed: 36741707
doi: 10.3389/fonc.2022.1014455
pmc: PMC9892904
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1014455Informations de copyright
Copyright © 2023 Vymazal, Kazda, Novak, Slanina, Sroubek, Klener, Hrbac, Syrucek and Rulseh.
Déclaration de conflit d'intérêts
JV and JS are PIs in Novocure-sponsored clinical trials, different from those presented in this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2020 Jul 15;10(1):11622
pubmed: 32669604
Front Oncol. 2020 Jul 03;10:840
pubmed: 32719739
Cancers (Basel). 2019 Feb 02;11(2):
pubmed: 30717372
J Clin Oncol. 1990 Jul;8(7):1277-80
pubmed: 2358840
Lung Cancer. 2013 Sep;81(3):445-450
pubmed: 23891283
J Neurooncol. 2017 Dec;135(3):621-627
pubmed: 28956223
Neurooncol Pract. 2021 Apr 20;8(4):426-440
pubmed: 34277021
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Neuro Oncol. 2016 Mar;18(3):303-5
pubmed: 26917587
Neuroimage Clin. 2016 Feb 26;11:316-321
pubmed: 27298760
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Clin Cancer Res. 2000 Jul;6(7):2585-97
pubmed: 10914698
J Neurooncol. 2019 Jan;141(2):467-473
pubmed: 30506499
Invest Radiol. 2019 Sep;54(9):559-564
pubmed: 31124800
J Clin Neurosci. 2018 Aug;54:7-13
pubmed: 29801989
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Crit Rev Oncol Hematol. 2017 Mar;111:60-65
pubmed: 28259296
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7
pubmed: 17551011
Oncologist. 2013 Jun;18(6):752-9
pubmed: 23697601
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Neurooncol. 2020 Apr;147(2):361-370
pubmed: 32060840